IPF Ofev denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for ipf ofev are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Ofev (nintedanib) for IPF as Duplicate Therapy

Cigna's duplicate-therapy edit flags cases where the claim system detects another active antifibrotic medication — most commonly another IPF agent — already on file for the same member. The plan's logic is that two antifibrotic drugs prescribed concurrently are not supported by standard clinical practice for idiopathic pulmonary fibrosis. In practice, the flag is frequently triggered in error: a prior prescription may still appear active in the claims history even though the patient has already stopped it, or two separate prescribers may have submitted claims close together during a transition.

## Why This Denial Is Appealable

A duplicate-therapy denial is administrative, not a judgment that Ofev is medically inappropriate for your diagnosis. If the duplication is a data artifact, it can be corrected on appeal with straightforward documentation. Even if a genuine therapy switch occurred, the medical record will show the clinical rationale for moving to Ofev, which is fully sufficient to overturn the denial.

## Federal Appeal Framework

• Internal appeal (Level 1): Required first. Cigna must decide within 30 days for non-urgent requests (72 hours for expedited).
• External review: If the internal appeal fails or Cigna does not decide in time, you have the right to independent external review under ACA §2719. For ERISA-governed employer plans, ERISA §503 guarantees a full-and-fair review. The window to request external review is generally up to four months from the denial notice; confirm the exact deadline on your Explanation of Benefits.
• Expedited option: If your prescriber certifies that the standard timeline would seriously jeopardize your health, request expedited review at every level.

## Documentation to Gather

1. Diagnosis confirmation — ICD-coded IPF diagnosis from pulmonology or rheumatology records, ideally including HRCT findings and PFT results. 2. Current medication list — A signed, dated medication reconciliation showing that no other antifibrotic is currently being taken, or if a switch is occurring, the exact stop date of the prior agent. 3. Prescription / claims clarification — Ask your pharmacy or prior prescriber to provide a letter confirming the prior drug was discontinued before Ofev was initiated. 4. Prescriber medical-necessity letter — Your physician should state the clinical reason for prescribing Ofev, confirm there is no concurrent duplicate antifibrotic therapy, and note any prior agent trial with dates and outcomes.

## Criteria-Mapping Structure

Print Cigna's published coverage policy for antifibrotics and list each requirement in one column. In the adjacent column, cite the exact chart entry or letter that satisfies it. Key points to address:

• Confirmed IPF diagnosis per guideline criteria (reference the applicable ATS/ERS/JRS/ALAT guideline organization, not specific numbers)
• No concurrent antifibrotic agent active at the time of prescribing
• Prescriber specialty and qualifications to manage IPF
• Medical-necessity rationale for this specific agent

Pairing this structured mapping with the clarification letter from your pharmacy or prior prescriber gives Cigna's reviewer everything needed to close the duplicate flag and approve the claim.